Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | TANGENT: Phase III trial of emactuzumab in tenosynovial giant cell tumors

Robin Jones, MBBS, MRCP, MD, Institute of Cancer Research, London, UK, discusses the primary analysis of the Phase III TANGENT (NCT05417789) trial evaluating emactuzumab, an intravenous monoclonal antibody targeting the CSF-1 receptor, in patients with tenosynovial giant cell tumors (TGCT). Compared with placebo, a short course of five infusions produced highly significant improvements in overall response rate, alongside meaningful gains across key functional endpoints, including physical function, range of motion, pain, and stiffness. Safety was manageable and consistent with prior data, positioning emactuzumab as a potential short-course alternative to chronic oral therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yes, so the TANGENT trial was a randomized phase 3 placebo-controlled trial of a CSF1R antibody in tenosynovial giant cell tumor, or TGCT. And the primary endpoint of the trial was response rate in the antibody arm compared to the placebo arm. And the trial met the primary endpoint, but also showed significant benefit for the antibody in terms of pain, function, and other quality of life measures...

Yes, so the TANGENT trial was a randomized phase 3 placebo-controlled trial of a CSF1R antibody in tenosynovial giant cell tumor, or TGCT. And the primary endpoint of the trial was response rate in the antibody arm compared to the placebo arm. And the trial met the primary endpoint, but also showed significant benefit for the antibody in terms of pain, function, and other quality of life measures. The notable thing about this trial compared to previous randomized trials in TGCT of CSF1R inhibitors was that this was a defined course of therapy for five cycles and over 75% of the patients continued to receive up to five cycles of treatment. This was the six-month analysis and of course we really eagerly await further follow-up because this trial will help to define the role of a defined course of therapy in TGCT.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.